MiniMed Group, Inc. MMED
At closeNov 3, 2026, 4:01 PM EST
After hours · Nov 3, 4:01 PM ET
- YTD
- +1.95%
- 1 year
- +1.95%
- Market cap
- 5.30B
- Revenue (ttm)
- 3.22B
- Profit margin
- -9.74%
- EPS (ttm)
- -1.53
- Shares out
- 281.35M
- Forward P/E
- 27.14
- YTD return
- +1.95%
- 1-year return
- +1.95%
- Volume
- 5.71M
- Avg volume
- 7.30M
- Open
- 18.77
- Previous close
- 18.90
- Day's range
- 18.51 – 19.05
- 52-week range
- 10.65 – 24.43
- Analysts
- Buy
- Price target
- 25.47 (+35.1%)
- Earnings date
- Dec 30, 2026
2Y +0.36 (+1.95%)
Key statistics
- Enterprise value
- 5.17B
- PEG ratio
- 0.00
- Price / sales
- 1.65
- Price / book
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 16.60%
- Free cash flow
- 0
- Total cash
- 207.00M
- Total debt
- 59.00M
- Return on equity
- -8.66%
- Short % of float
- 72.56%
- 50-day average
- 20.12
- 200-day average
- 16.61
Analyst view
Consensus: buy
- Target (low)
- 15.00
- Target (mean)
- 25.47
- Target (high)
- 30.00
- Strong buy0
- Buy12
- Hold3
- Sell0
- Strong sell1
Next earnings
Dec 30, 2026
Expected Dec 30, 2026. Consensus EPS estimate 0.10105.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 30, 2026 | Oct 30, 2026 | 0.1238 | — | — | — |
| Sep 1, 2026 | Jul 30, 2026 | 0.1241 | 0.12 | 0.00 | -3.30% |
| Jun 3, 2026 | Apr 24, 2026 | -0.14907 | -0.68 | -0.53 | -356.16% |
| Apr 17, 2026 | Jan 31, 2026 | 0.1702 | -0.16 | -0.33 | -194.01% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | init | — | Hold |
| Oct 8, 2026 | Mizuho | main | Outperform | Outperform |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Sep 24, 2026 | Truist Securities | init | — | Buy |
| Sep 3, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 2, 2026 | Citigroup | main | Buy | Buy |
About MiniMed Group, Inc.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- minimed.com
News
MiniMed Appoints Dr. David Segal as Chief Medical Officer 
Bears Load Up on Ondas, Dutch Bros and 8 More Stocks — Is a Squeeze Brewing? 
How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King? 
MiniMed Announces Board of Directors for its Next Chapter as an Independent Company 
MiniMed Names Kevin E. Lofton Board Chair, Effective Separation From Medtronic 
MiniMed Announces Board of Directors for its Next Chapter as an Independent Company 
MiniMed Completes Separation from Medtronic 
Medtronic Completes Separation of MiniMed Group, Inc. 
Jim Cramer: This Health Care Stock Is A ‘Winner’, X-Energy Is ‘Losing Too Much Money’ 
Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
Your note
Sign in to keep a note on MMED — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANDRASENA GILLIAN | Officer | Stock Award(Grant) | Oct 14, 2026 | 174,545 |
| DALLARA QUE | Chief Executive Officer | Stock Award(Grant) | Jun 30, 2026 | 916,099 |
| DENTON SHEILA A | General Counsel | Stock Award(Grant) | Sep 30, 2026 | 58,939 |
| DIANATY ALI | Chief Technology Officer | Stock Award(Grant) | Oct 14, 2026 | 326,266 |
| EISENBERG GLENN A | Director | Stock Award(Grant) | Oct 8, 2026 | 25,684 |
| GROSSMAN DONALD KEITH | Director | Stock Award(Grant) | Oct 8, 2026 | 25,684 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Massachusetts Financial Services Co. | 2.96% | 8,334,738 | 157.11M | Jun 29, 2026 |
| Millennium Management Llc | 1.09% | 3,060,615 | 57.69M | Jun 29, 2026 |
| Citadel Advisors Llc | 1.02% | 2,865,703 | 54.02M | Jun 29, 2026 |
| Longaeva Partners L.P. | 1.00% | 2,812,970 | 53.02M | Jun 29, 2026 |
| Blackrock Inc. | 0.71% | 1,996,489 | 37.63M | Jun 29, 2026 |
| Sessa Capital IM, L.P. | 0.71% | 2,000,000 | 37.70M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MFS SERIES TRUST XI-MFS Mid Cap Value Fund | 1.52% | 4,277,567 | 80.63M | Jun 29, 2026 |
| Fidelity Select PORT.s-Select Medical Technology and Devices PORT. | 0.66% | 1,850,000 | 34.87M | Aug 30, 2026 |
| MFS SERIES TRUST XIII-MFS New Discovery Value Fund | 0.32% | 888,545 | 16.75M | Aug 30, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.31% | 866,942 | 16.34M | Aug 30, 2026 |
| First TRT Exch-Trd Fd.-First TRT US Eqy. Opportunities ETF | 0.29% | 813,147 | 15.33M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.27% | 749,532 | 14.13M | Sep 29, 2026 |